Major Estimate Revision • May 15
Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$174.4m to US$168.4m. 2026 losses expected to reduce from -US$0.517 to -US$0.412 per share. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target of US$2.46 unchanged from last update. Share price fell 21% to US$1.12 over the past week. Reported Earnings • May 11
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: US$0.027 loss per share (improved from US$1.44 loss in 1Q 2025). Revenue: US$37.2m (flat on 1Q 2025). Net loss: US$8.28m (loss narrowed 98% from 1Q 2025). Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 79%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Announcement • Apr 25
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 03, 2026 Pacific Biosciences of California, Inc., Annual General Meeting, Jun 03, 2026. Price Target Changed • Apr 23
Price target decreased by 8.1% to US$2.38 Down from US$2.58, the current price target is an average from 6 analysts. New target price is 51% above last closing price of US$1.57. Stock is up 38% over the past year. The company is forecast to post a net loss per share of US$0.52 next year compared to a net loss per share of US$1.82 last year. Announcement • Apr 17
Pacific Biosciences of California, Inc. to Report Q1, 2026 Results on May 07, 2026 Pacific Biosciences of California, Inc. announced that they will report Q1, 2026 results on May 07, 2026 Announcement • Apr 16
Pacbio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples PacBio and Covaris announced a joint workflow has been developed for robust HiFi sequencing of formalin-fixed, paraffin-embedded (FFPE) tissue samples. The protocol will be formally presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting. This solution integrates Covaris’ truXTRAC FFPE extraction technology with PacBio’s Kinnex library preparation and sequencing on the Revio system, delivering a streamlined workflow from sample to sequencing. FFPE samples are among the most abundant and clinically relevant sources of biological material, particularly in oncology research. However, DNA damage and fragmentation caused by fixation have historically limited their compatibility with long-read sequencing. The combined Covaris–PacBio workflow is designed to help address these challenges, enabling researchers to generate high-quality HiFi sequencing data from archived tumor samples. The workflow leverages Covaris’ Adaptive Focused Acoustics (AFA)-based truXTRAC FFPE extraction method to recover longer DNA fragments, up to 5,000 base pairs, from FFPE tissues. PacBio’s Kinnex library preparation concatenates these fragments into longer molecules suitable for HiFi sequencing, improving efficiency and data quality. In studies across brain, kidney, and uterine tumor samples, the workflow produced more than 100 million HiFi reads per sample, with mean read lengths of 750–1,500 base pairs. The data enabled detection of over 11,000 structural variants and more than 5 million small variants per sample, with approximately 60% phased into haplotypes. By comparison, short-read sequencing of FFPE tissue typically detects 3,000–7,000 structural variants per sample, less than half the yield achieved here, due to limitations in spanning complex rearrangements and repetitive regions. Notably, while short-read approaches produce comparable small variant counts, their shorter read lengths generally limit the ability to directly phase variants into haplotypes, often requiring statistical inference or specialized library methods. As a result, the approximately 60% direct phasing achieved with this workflow represents a distinctive and potentially clinically meaningful advantage of long-read HiFi sequencing. The combined workflow demonstrates consistent performance across diverse tissue types and varying DNA quality, enabling comprehensive genomic profiling, including structural variant detection and somatic mutation phasing. By unlocking FFPE samples for HiFi sequencing, PacBio and Covaris are helping transform underutilized archives into powerful datasets: enriching the context and scale of data available for AI-driven discovery and enabling new biological findings that were previously out of reach. Recent Insider Transactions • Apr 07
CFO & Principal Accounting Officer recently sold US$121k worth of stock On the 1st of April, James Gibson sold around 88k shares on-market at roughly US$1.37 per share. This transaction amounted to 6.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$752k. This was James' only on-market trade for the last 12 months. Announcement • Mar 05
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 PacBio announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors, to serve as a Class I director effective as of March 3, 2026. As of the Effective Date, the Board also appointed Dr. Gibson as a member of the Company’s Science and Technology Committee. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion, a clinical-stage biotechnology company that has built one of the industry’s most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional biology, and artificial intelligence. He led the company from inception through significant capital formation, strategic partnerships, and a successful public listing, establishing Recursion as a leader at the intersection of computation and biology. At Recursion, Dr. Gibson oversaw the development of a proprietary data platform capable of generating and analyzing massive multimodal datasets spanning drug discovery, translation, clinical and electronic health records (EHR), enabling the training of machine learning models to map complex biological relationships and accelerate clinical development and patient selection. He and his team built an organization designed around computational biology, software engineering, automation, and scalable infrastructure, positioning the company at the forefront of AI-enabled therapeutics development. Recent Insider Transactions • Feb 25
President recently sold US$752k worth of stock On the 18th of February, Christian O. Henry sold around 473k shares on-market at roughly US$1.59 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Christian O. has been a net seller over the last 12 months, reducing personal holdings by US$770k. Recent Insider Transactions Derivative • Feb 18
President notifies of intention to sell stock Christian O. Henry intends to sell 606k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of February. If the sale is conducted around the recent share price of US$1.58, it would amount to US$956k. For the year to December 2019, Christian O.'s total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Christian O. has owned 696.81k shares directly. Company insiders have collectively sold US$71k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 13
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$1.82 loss per share (further deteriorated from US$1.13 loss in FY 2024). Revenue: US$160.0m (up 3.9% from FY 2024). Net loss: US$546.4m (loss widened 76% from FY 2024). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.6%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. Announcement • Feb 03
Illumina Cambridge, Ltd. acquired DNA sequencing technology & related intellectual property of Pacific Biosciences of California, Inc. (NasdaqGS:PACB) for $50 million. Illumina Cambridge, Ltd. acquired DNA sequencing technology & related intellectual property of Pacific Biosciences of California, Inc. (NasdaqGS:PACB) for $50 million on January 30, 2026. A cash consideration of $50 million will be paid by Illumina Cambridge, Ltd. As part of consideration, $50 million is paid towards assets of DNA sequencing technology & related intellectual property of Pacific Biosciences of California, Inc.
Andrew Hoffman, Douglas Schnell, Zachary Meyers, Broderick Henry Jr. of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor for Pacific Biosciences of California, Inc. Jon Olsen and Adam Welland of Sidley Austin LLP, London acted as legal advisor for Illumina,?Inc.
Illumina Cambridge, Ltd. completed the acquisition of DNA sequencing technology & related intellectual property of Pacific Biosciences of California, Inc. (NasdaqGS:PACB) on January 30, 2026. Announcement • Jan 28
Pacific Biosciences of California, Inc. to Report Q4, 2025 Results on Feb 12, 2026 Pacific Biosciences of California, Inc. announced that they will report Q4, 2025 results on Feb 12, 2026 Announcement • Jan 13
PacBio HiFi Announces it has Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) PacBio announced that a UW Medicine and Seattle Children’s research effort led by Danny Miller, MD, PhD, and Alexandra Keefe, MD, PhD, will employ PacBio HiFi whole-genome sequencing as the first-line approach to investigate Sudden Unexplained Death in Childhood (SUDC). Backed by the SUDC Foundation and with in-kind support from PacBio, the project will sequence each child and their parents, prioritizing long-read HiFi data for comprehensive variant detection. Additionally, the University of Washington team will join the HiFi Solves Global Consortium, which brings together institutions around the world to study the value HiFi-based human genome sequencing may have in clinical research applications and to furtherunderstanding of genetic diseases. Applying HiFi sequencing as a first-tier assay is designed to consolidate and simplify the laboratory workflow especially in the context of post-mortem tissue and newborn dried blood spots as challenging sample inputs. The researchers hope to increase diagnostic yield by resolving complex variants like structural variants and tandem repeats and by including parents to elucidate de novo and inherited contributors to risk. Announcement • Jan 08
PacBio and UC Davis Researchers Introduce CiFi, A New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from A Single SMRT Cell PacBio announced CiFi, a new community-developed method that enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited. By integrating chromatin conformation capture (3C) with PacBio HiFi long-read sequencing, CiFi delivers multi-contact reads and longer fragments that significantly increase the information content of proximity ligation experiments in a single Revio sequencing run. A defining publication just released in Nature Communications by researchers in the Megan Dennis Laboratory at the University of California, Davis, shows how CiFi addresses long-standing limitations of short-read Hi-C by generating long, highly accurate reads that capture multiple chromatin interactions within a single molecule. The new method offers several advantages tailored to the needs of genome biology, biodiversity studies, and functional genomics. These include improved mapping in repetitive regions, removing obstacles around low input performance, enabling multi-contact resolution, and saving project time and complexity through single platform simplicity. When paired with Revio SPRQ chemistry, CiFi makes it possible to generate reference-quality assemblies using fewer cells, fewer libraries, and fewer sequencing runs. This lowers barriers for genome projects that have been limited by cost, complexity, or sample availability. The resulting uncurated assemblies achieved scaffold N50 values exceeding one hundred million base pairs, with telomeric sequence detected at both ends of many scaffolds. These results show that the UC Davis developed CiFi method, combined with HiFi sequencing, can routinely deliver chromosome scale, reference quality assemblies using only one sequencing run. Price Target Changed • Jan 06
Price target increased by 9.4% to US$2.50 Up from US$2.29, the current price target is an average from 7 analysts. New target price is 26% above last closing price of US$1.98. Stock is down 1.0% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$1.13 last year. Price Target Changed • Dec 16
Price target increased by 9.0% to US$2.36 Up from US$2.16, the current price target is an average from 7 analysts. New target price is 11% above last closing price of US$2.12. Stock is up 3.4% over the past year. The company is forecast to post a net loss per share of US$1.85 next year compared to a net loss per share of US$1.13 last year. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of Scientific Advisory Board Jay Shendure was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: US$0.13 loss per share (improved from US$0.22 loss in 3Q 2024). Revenue: US$38.4m (down 3.8% from 3Q 2024). Net loss: US$38.0m (loss narrowed 37% from 3Q 2024). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Announcement • Nov 05
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China PacBio announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products Administration (NMPA) in China. This marks the world's first regulatory clearance of a clinical-grade long-read sequencer, a milestone led by Berry Genomics that signals a new era for precision medicine and high-accuracy genomic testing in China. High-incidence genetic disorders such as thalassemia often involve complex variant types that are difficult or impossible to detect using short-read sequencing. With the Sequel II CND x system, clinicians can now access a complete picture of the genome in a single test--capturing single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), structural variants (SVs), and repeat expansions with exceptional accuracy. When paired with Berry's newly approved clinical thalassemia assay and software system, this approval delivers the first end-to-end long-read sequencing workflow for China's hospitals and diagnostic laboratories, optimized for carrier, prenatal, newborn, and rare disease testing. As a company with strong R&D capability, Berry Genomics pioneered the first NGS-based genetic test, NIPT, in China back in 2010. The company currently provides NGS-based tests for many genetic diseases and cancer from prevalence to adulthood. Berry Genomics has around 1500 employees dedicating to developing products and providing services for over 4000 organizations and facilities home and abroad, including hospitals, research institutions, universities and corporations. Announcement • Oct 23
Pacific Biosciences of California, Inc. to Report Q3, 2025 Results on Nov 05, 2025 Pacific Biosciences of California, Inc. announced that they will report Q3, 2025 results on Nov 05, 2025 Announcement • Oct 16
Pacific Biosciences of California, Inc. Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities Pacific Biosciences of California, Inc. announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to deliver PacBio's most affordable HiFi genome to date. Customers operating at scale could see as much as a 40% reduction from current costs, down to a price of less than $300 per genome. Beta testing of SPRQ-Nx chemistry on the higher throughput Revio is expected to begin in November 2025, with full commercial availability planned in 2026. Beta participants will be able to purchase 384 genomes of sequencing reagents for approximately $250 per genome. At launch, Revio systems running SPRQ-Nx will produce complete, multiomic native long-read genomes at the lowest cost in the market. PacBio intends to achieve these cost savings by enabling multiple runs per SMRT Cell while maintaining output per run, which will improve efficiency, reduce waste, and preserve PacBio's hallmark accuracy and data richness. With the increased demand for HiFi data in large-scale, multi-year population studies, PacBio plans to provide to long-term support for the Revio and Vega platforms through 2032. Interested customers can register for early-access to SPRQ-Nx through PacBio's updated Technology Page, or visit booth #919 at ASHG 2025 for more details. Announcement • Sep 23
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes PacBio announced its entry into the high-throughput carrier screening market with a significantly expanded and enhanced suite of PureTarget products. The updated solutions leverage PacBio's highly accurate HiFi sequencing technology to allow clinical laboratories to consolidate multiple specialized assays into a single, scalable test capable of resolving some of the most challenging genes associated with inherited conditions. Recent research shows that up to 71% of individuals carry at least one pathogenic variant, highlighting the growing importance of carrier screening in family planning. The use of carrier screening is rapidly expanding across commercial labs, health systems, and government-funded programs worldwide. The analysis of technically difficult hereditary genes - such as those linked to fragile X syndrome (FMR1), spinal muscular atrophy (SMN1), and Friedreich Ataxia (FXN) - has historically required multiple technologies and specialized workflows. This fragmentation slowed adoption of comprehensive carrier screening, increased costs, and limited global access. PacBio's expanded PureTarget portfolio now provides laboratories with broad, accurate carrier screening solutions, including coverage of all challenging tier 3 genes identified in the American College of Medical Genetics technical standard. The panels are available in 24- and 96-sample kit formats, with three complementary configurations designed to meet a range of laboratory needs: A carrier screening panel for inherited reproductive conditions; A repeat expansion disorder panel for neurological diseases; A control panel to support custom assay design and validation. Together, these kits allow laboratories to replace multiple specialized assays with a single streamlined workflow, adaptable from targeted clinical programs to national population-screening initiatives. With the addition of a carrier screening panel, expanded disease gene content, automation support, and custom panel design, PureTarget gives laboratories the flexibility to scale programs securely and efficiently. PacBio's entry into this market shows a clear commitment to simplifying complex genomic testing and expanding access to comprehensive screening worldwide. Reported Earnings • Aug 10
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: US$0.14 loss per share (improved from US$0.64 loss in 2Q 2024). Revenue: US$39.8m (up 10% from 2Q 2024). Net loss: US$41.9m (loss narrowed 76% from 2Q 2024). Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Announcement • Aug 05
PacBio Announces the Release of the Platinum Pedigree: A Long-Read Benchmark for Genetic Variants PacBio announced the results of a study published in Nature Methods describing a new, comprehensive truth-set of genomic variation which characterizes simple and complex variation. These improved benchmarks were used to retrain Google's DeepVariant, a popular AI-based variant calling tool, resulting in a 34% reduction in erroneously called variants. This resource (the Platinum Pedigree) was built by scientists from PacBio in collaboration with researchers at the University of Washington, the University of Utah, and several other institutions. Combining inheritance-based validation with long-read sequencing, this benchmark accurately characterizes variants, even in difficult, repeat rich regions of the genome, producing the most complete view of validated genetic variation to date. The Platinum Pedigree dataset was developed using deep sequencing from three sequencing platforms across a 28-member, multi-generational family (CEPH-1463). The dataset introduces the first large pedigree-validated tandem repeat and structural variant truth sets. It also adds more than 200 million bases extending the benchmark regions to 2.77 Gb, including difficult-to-map areas such as segmental duplications and low-complexity regions. As a demonstration of the value of improved benchmarks to improve AI and ML methods, the researchers retrained Google's DeepVariant - a popular software tool that employs deep learning to identify genetic variants - using the Platinum Pedigree benchmark data. This updated DeepVariant model reduced errors by up to 34% genome-wide, including even higher gains in the most challenging regions of the genome. A New Standard for Clinical and Population Genomics: The Platinum Pedigree benchmark is freely available and already being used by scientists to develop new sequence analysis tools and validate clinical sequencing workflows. It also provides a roadmap for future benchmarking efforts, especially those involving more complete genomes like T2T-CHM13. The full dataset, analysis code, and pipelines are publicly available at: The study, "The Platinum Pedigree: A long-read benchmark for genetic variants," was published in Nature Methods on August 4, 2025. It was led by scientists at PacBio, the University of Washington, and University of Utah, with support from the NIH and Howard Hughes Medical Institute. Announcement • Jul 22
Pacific Biosciences of California, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Pacific Biosciences of California, Inc. announced that they will report Q2, 2025 results on Aug 07, 2025 Major Estimate Revision • May 19
Consensus EPS estimates fall by 109% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$160.2m to US$156.8m. Losses expected to increase from US$0.73 per share to US$1.52. Life Sciences industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$2.14 to US$2.03. Share price fell 5.9% to US$1.04 over the past week. Price Target Changed • May 16
Price target decreased by 8.9% to US$2.03 Down from US$2.23, the current price target is an average from 11 analysts. New target price is 96% above last closing price of US$1.04. Stock is down 49% over the past year. The company is forecast to post a net loss per share of US$1.52 next year compared to a net loss per share of US$1.13 last year. Reported Earnings • May 09
First quarter 2025 earnings: EPS misses analyst expectations First quarter 2025 results: US$1.44 loss per share (further deteriorated from US$0.29 loss in 1Q 2024). Revenue: US$37.2m (down 4.3% from 1Q 2024). Net loss: US$426.1m (loss widened 445% from 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Announcement • Apr 28
Pacific Biosciences of California, Inc. Announces Plans to Improve Methylation Detection in HiFi Chemistry Pacific Biosciences of California, Inc. announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at the The Chinese University of Hong Kong (CUHK) and Centre for Novostics. The licensed technology is designed to enhance PacBio HiFi sequencing with improved detection of DNA base modifications--including 5-hydroxymethylcytosine (5mC) and hemimethylated 5-methylcytosine(5mC)--in native DNA. PacBio plans to bring these capabilities to its Revio and Vega systems, building on its existing 5mC support to deliver even more comprehensive epigenomic insights as part of standard HiFi whole-genome sequencing workflows. The newly licensed technology includes an enhanced AI deep learning framework known as Holistic Kinetic Model 2 (HK2), which integrates convolutional and transformer layers to model local and long-range kinetic features with extraordinary precision. HK2 is designed to significantly improve the accuracy of 5mC and N6-methyladenine (6mA) detection and introduces native 5hmC calling in single molecules--a first for HiFi sequencing. HiFi sequencing, available on both the Revio and Vega platforms, provides a comprehensive and simultaneous readout of the genome and epigenome from native DNA without the need for chemical conversion, additional sample preparation, or parallel workflows. The new capabilities from the HK2 model will be delivered to existing customers through software updates, with no changes to sequencing protocols and no additional cost. CUHK, together with Take2 Technologies Limited, a Hong Kong-based biotechnology company, pioneered robust 5mC detection in 2021 using the PacBio platform. PacBio introduced on-instrument 5mC detection in April 2022 and extended support to 6mA in December 2024 for Fiber-seq chromatin architecture studies. HK2 is designed to push detection performance to new levels of accuracy. Importantly, HK2 will also enable strand-specific 5mC analysis, which opens new opportunities to study hemimethylation--an emerging epigenetic signal. HiFi 5-base sequencing has already been adopted by pioneering institutions such as Children's Mercy Kansas City, the first to use comprehensive genomic and epigenomic profiling in a clinical setting. The licensing of HK2 marks another milestone in PacBio's continued leadership in long-read epigenomics. Combined with the high accuracy and long read lengths of HiFi sequencing, HK2 delivers a uniquely powerful tool for understanding the full landscape of genome function-- across both sequence and modification. Announcement • Apr 25
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 04, 2025 Pacific Biosciences of California, Inc., Annual General Meeting, Jun 04, 2025. Announcement • Apr 09
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025 Pacific Biosciences of California, Inc. reiterated earnings guidance for the full year 2025. For the year, the company reiterated its previous financial guidance including: revenue to be $155 million to $170 million. Announcement • Mar 27
Pacific Biosciences of California, Inc. Appoints Jim Gibson as Chief Financial Officer, Effective March 31, 2025 PacBio announced Jim Gibson will join and be appointed as the company’s new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley’s most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across four entities. Prior to Sequoia, Mr. Gibson was CFO at Willow Innovations, where he helped raise $132 million and positioned the company for its next stage of growth. Additionally, he has held executive roles at GoDaddy, Tesla, Apple, Netflix, and Affymetrix, where he helped scale businesses, integrate acquisitions, and deliver over $1B in raised capital across his career. Gibson holds a B.A. in Business Economics with Honors from the University of California, Santa Barbara, and is a licensed CPA in California (inactive). Reported Earnings • Mar 18
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: US$1.13 loss per share. Revenue: US$154.0m (down 23% from FY 2023). Net loss: US$309.9m (loss widened 1.0% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Major Estimate Revision • Feb 22
Consensus revenue estimates fall by 14% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$187.2m to US$161.8m. Forecast losses increased from -US$0.709 to -US$0.753 per share. Life Sciences industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$3.02 to US$2.67. Share price fell 17% to US$1.54 over the past week. Recent Insider Transactions • Feb 21
President recently sold US$488k worth of stock On the 18th of February, Christian O. Henry sold around 260k shares on-market at roughly US$1.88 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Christian O. has been a net seller over the last 12 months, reducing personal holdings by US$730k. Recent Insider Transactions Derivative • Feb 19
President notifies of intention to sell stock Christian O. Henry intends to sell 260k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of February. If the sale is conducted around the recent share price of US$1.88, it would amount to US$488k. For the year to December 2018, Christian O.'s total compensation was 9% salary and 91% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Christian O.'s direct individual holding has increased from 299.89k shares to 388.48k. Company insiders have collectively bought US$159k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Feb 14
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: US$1.12 loss per share. Revenue: US$154.0m (down 23% from FY 2023). Net loss: US$308.7m (flat on FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Announcement • Feb 03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service, Effective February 10, 2025 PacBio announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom Video Communications, Microsoft Corporation, and Thermo Fisher Scientific, where, as part of Life Technologies, he was Chief Commercial Officer for the Life Sciences Solutions Group. In his new role, Mr. Ruggiero will oversee PacBio’s global sales and service operations, focusing on accelerating the adoption of the company’s sequencing platforms and enhancing customer support worldwide. Mr. Ruggiero is expected to start on February 10, 2025. Announcement • Jan 31
Pacific Biosciences of California, Inc. to Report Q4, 2024 Results on Feb 13, 2025 Pacific Biosciences of California, Inc. announced that they will report Q4, 2024 results on Feb 13, 2025 Announcement • Jan 30
PacBio Announces Appointment of Chris Smith to Board of Directors PacBio announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc., a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company’s continued growth and innovation in precision medicine. Prior to NeoGenomics, Mr. Smith served as Chairman and CEO of Ortho Clinical Diagnostics which was sold to Quidel Corporation in December 2021. Prior to that, Mr. Smith was the CEO of Cochlear Limited and has served on several different boards of directors in both public and private companies. Mr. Smith holds a Bachelor of Science Degree in Journalism from Texas A&M University. While Mr. Smith is joining the Board of PacBio, David Meline is resigning from the Board, effective today. Mr. Meline has served on the Board since 2023 and has played an important role in helping the Board drive the business and strategy of the Company. Recent Insider Transactions • Jan 14
Chief Operating Officer recently sold US$70k worth of stock On the 10th of January, Mark Van Oene sold around 34k shares on-market at roughly US$2.03 per share. This transaction amounted to 8.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Mark has been a net seller over the last 12 months, reducing personal holdings by US$378k. Announcement • Jan 14
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics PacBio announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tests with a single, more comprehensive approach. The study, led by Christian Gilissen and Lisenka Vissers of Radboudumc, used PacBio’s Revio platform and HiFi long reads to analyze 100 challenging patient samples where the genetic causes of rare diseases had been difficult to identify in previous investigations using short reads combined with various supplementary tests. HiFi sequencing results from these samples identified an impressive 93% of pathogenic variants, possibly enhancing cost-effective diagnostic implementation. HiFi technology also enabled the detection of genetic variants missed by short-read approaches, including complex structural variants and DNA methylation abnormalities to be identified. Metrics Demonstrating Momentum Towards Clinical Genomics Implementation: In support of this study and a broader transition to HiFi long-reads, PacBio and Radboudumc are accelerating efforts to study bringing this approach into clinical practice. The collaboration is advancing rapidly, with recent milestones demonstrating measurable progress: Nearly 1,000 samples processed: As of January 10, 2025, 981 samples have been sequenced, with 862 fully analyzed since August 2024. Operational improvements: Automated library preparation now enables 24 samples per run, with plans to scale up to 96 samples per run for even greater throughput. Streamlined workflows: Advanced protocols and a graphical user interface are being optimized to support future diagnostics for all variant types, with the first-tier diagnostic rollout targeted for summer 2025. Commitment to 5,000 diagnostic genomes: In the fourth quarter of 2024, Radboudumc expanded its Revio instrument fleet to support an order for 5,000 genomes on SPRQ chemistry. New Risk • Nov 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$143m net loss in 3 years). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Significant insider selling over the past 3 months (US$313k sold). Reported Earnings • Nov 08
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: US$0.22 loss per share (improved from US$0.26 loss in 3Q 2023). Revenue: US$40.0m (down 28% from 3Q 2023). Net loss: US$60.7m (loss narrowed 9.2% from 3Q 2023). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) exceeded analyst estimates by 7.0%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Announcement • Nov 07
PacBio Unveils the Vega System PacBio announced the Vega system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality of the Revio system, PacBio’s high-throughput long-read sequencer, into a compact, lower-throughput benchtop platform. Offering exceptional data accuracy with HiFi technology, fast turnaround time, and a U.S. list price of $169,000, Vega is the perfect solution for researchers looking to adopt long-read sequencing across a variety of applications, including targeted sequencing, RNA sequencing, and small genome sequencing. Vega is compatible with the existing HiFi ecosystem for library preparation and data analysis enabling researchers to perform any HiFi sequencing application. With one SMRT cell per run, Vega has a throughput of 600 full-length RNA samples per year using the Kinnex full-length RNA kit, 9,600 samples using the PureTarget repeat expansion panel, or 200 human genomes. Vega is designed to make HiFi long-read sequencing more affordable and accessible to a broader range of researchers, helping them unlock new long-read sequencing applications. Vega offers the same on-board computing features available on other PacBio instruments, but features an easy-to-operate, integrated workflow with only two consumables. To further simplify setup, PacBio is offering SMRT Link Cloud software to allow customers to manage instruments without on-premises compute. PacBio is now accepting orders for Vega systems, which it plans to begin shipping in the first quarter of 2025. Vega will be on display at PacBio’s booth at the American Society of Human Genetics annual meeting taking place this week in Denver, Colorado. Announcement • Oct 29
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems PacBio announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also increase the Revio system’s output, which together with improved analysis methods, enables customers to reduce their sequencing cost per genome by up to 50 percent. Paired instrument software enhancements will also improve the accuracy of methylation calling and add detection of new types of methylation marks providing customers with a rich, multiomic view of every sample. The SPRQ chemistry will increase the efficiency of loading on Revio SMRT Cells, reducing DNA input requirements to just 500 ng, a four-fold reduction. The chemistry will also improve sequencing performance, providing a 33% increase in sequencing yield per SMRT Cell. Collectively, these enhancements will enable each Revio instrument to sequence up to 2,500 human whole genomes per year at a cost of just under $500 per human genome. In addition, a SMRT Link and instrument software upgrade paired with the release of SPRQ chemistry provides new DNA methylation callers that greatly increase the multiomics capabilities of every Revio run. The software brings improved accuracy for calling 5mC, making HiFi sequencing an attractive alternative to methylation arrays. It also adds a new capability to call 6mA, which is used as a marker of open chromatin in the Fiber-seq assay, providing DNA, methylation, and chromatin accessibility all from a single DNA input and sequencing run. PacBio will present data on the new SPRQ chemistry at a workshop at the American Society of Human Genetics annual meeting taking place in Denver, Colorado, November 5-9, 2024. The SPRQ chemistry and SMRT Link software are available for order starting immediately and will begin shipping in December 2024. Announcement • Oct 11
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Pacific Biosciences of California, Inc. announced that they will report Q3, 2024 results on Nov 07, 2024 Recent Insider Transactions • Sep 19
President recently sold US$173k worth of stock On the 16th of September, Christian O. Henry sold around 99k shares on-market at roughly US$1.75 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Christian O. has been a net seller over the last 12 months, reducing personal holdings by US$723k. Recent Insider Transactions Derivative • Sep 18
President notifies of intention to sell stock Christian O. Henry intends to sell 99k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of September. If the sale is conducted around the recent share price of US$1.75, it would amount to US$173k. For the year to December 2018, Christian O.'s total compensation was 9% salary and 91% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2023, Christian O.'s direct individual holding has increased from 235.78k shares to 299.89k. Company insiders have collectively sold US$305k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Aug 22
Chief Operating Officer recently sold US$63k worth of stock On the 16th of August, Mark Van Oene sold around 38k shares on-market at roughly US$1.66 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Mark has been a net seller over the last 12 months, reducing personal holdings by US$549k. Recent Insider Transactions Derivative • Aug 19
Chief Operating Officer notifies of intention to sell stock Mark Van Oene intends to sell 38k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of August. If the sale is conducted around the recent share price of US$1.66, it would amount to US$63k. Since March 2024, Mark has owned 279.38k shares directly. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Aug 16
Consensus EPS estimates fall by 47% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$179.0m to US$168.1m. Losses expected to increase from US$0.93 per share to US$1.37. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$4.25 to US$3.92. Share price was steady at US$1.69 over the past week. Price Target Changed • Aug 13
Price target decreased by 7.8% to US$3.92 Down from US$4.25, the current price target is an average from 12 analysts. New target price is 163% above last closing price of US$1.49. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.29 next year compared to a net loss per share of US$1.21 last year. Reported Earnings • Aug 08
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: US$0.64 loss per share (further deteriorated from US$0.28 loss in 2Q 2023). Revenue: US$36.0m (down 24% from 2Q 2023). Net loss: US$173.3m (loss widened 148% from 2Q 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 168%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. Announcement • Aug 08
Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Pacific Biosciences of California, Inc. reported goodwill impairment for the second quarter ended June 30, 2024. For the quarter, the company reported goodwill impairment of $93,200,000. Announcement • Jul 16
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Pacific Biosciences of California, Inc. announced that they will report Q2, 2024 results on Aug 07, 2024 Announcement • Jul 03
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Major Estimate Revision • May 16
Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$193.1m to US$186.5m. 2024 losses expected to reduce from -US$1.04 to -US$0.928 per share. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$5.82 to US$4.68. Share price rose 28% to US$2.15 over the past week. Price Target Changed • May 12
Price target decreased by 7.2% to US$5.40 Down from US$5.82, the current price target is an average from 10 analysts. New target price is 205% above last closing price of US$1.77. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.94 next year compared to a net loss per share of US$1.21 last year. Reported Earnings • May 10
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: US$0.29 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$38.8m (flat on 1Q 2023). Net loss: US$78.2m (loss narrowed 11% from 1Q 2023). Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 3.2%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. Announcement • May 01
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024 Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024, at 09:00 Pacific Standard Time. Agenda: To vote for the four nominees for company's Class II directors; to consider the ratification of the appointment of Ernst & Young LLP as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider the approval of the non-binding advisory vote to approve the compensation of company's named executive officers for the year ended December 31, 2023; to consider the amendment to company's certificate of incorporation to declassify our Board of Directors; and to consider other matters. New Risk • Apr 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$176m net loss in 3 years). Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.1m sold). Price Target Changed • Apr 17
Price target decreased by 16% to US$8.44 Down from US$10.05, the current price target is an average from 10 analysts. New target price is 503% above last closing price of US$1.40. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.03 next year compared to a net loss per share of US$1.21 last year. Major Estimate Revision • Apr 17
Consensus revenue estimates decrease by 11%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$239.1m to US$212.5m. EPS estimate increased from -US$1.04 to -US$1.03 per share. Life Sciences industry in the US expected to see average net income growth of 12% next year. Consensus price target down from US$11.24 to US$9.45. Share price fell 61% to US$1.40 over the past week. 
